Bangyun Medical

Based in Shanghai, China and founded in 2019, Shanghai Bangyun Medical Technology Co. , Ltd. , trading as Bangyun Medical, is a medical device developer focusing on the R&D, production, and sales of high-end surgical wound closure consumables and instruments. In March 2026, Bangyun Medical raised approximately 100 million in angel funding led by Dalton Venture, with participation from Jinding Capital.

Its products cover clinical departments including general surgery, gynecology, urology, and plastic surgery. The company is committed to providing high-quality wound closure solutions for doctors and patients through localized, compliant production and clinically-oriented innovation. The company generates revenue by doing R&D, and providing medical devices and other related products. The Angel funding raised in March 2026 will be mainly used for: expanding the production capacity of high-end products such as absorbable barbed sutures and antibacterial sutures, and tackling the challenges of establishing a local raw material supply chain; developing and conducting clinical trials of the world's first BESTURE novel wound healing acceleration product; and expanding the professional sales and marketing operations team.